Stock Research: Knight Therapeutics

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Knight Therapeutics

TSX:GUD CA4990531069
37
  • Value
    96
  • Growth
    21
  • Safety
    Safety
    48
  • Combined
    56
  • Sentiment
    16
  • 360° View
    360° View
    37
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Knight Therapeutics Inc. is a specialty pharmaceutical company. It operates in the pharmaceutical industry, developing, acquiring, and distributing pharmaceutical products. The company operates in Canada, Latin America, and select international markets. In the last fiscal year, the company had a market cap of $442 million, profits of $121 million, and revenue of $258 million, with 745 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 37 (better than 37% compared with alternatives), overall professional sentiment and financial characteristics for the stock Knight Therapeutics are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four metrics below average for Knight Therapeutics. The only rank that is above average is the consolidated Safety Rank at 96, which means that the company has a financing structure that is safer than those of 96% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the Value, Growth and Sentiment Ranks are all below average. The consolidated Value Rank has a less desirable rank of 48, which means that the share price of Knight Therapeutics is on the high side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 21, which implies that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. Finally, the consolidated Sentiment Rank is also low at a rank of 16, which means that professional investors are more pessimistic about the stock than for 84% of alternative investment opportunities. While Safety is strong, it’s not the most critical indicator, so we suggest proceeding with caution if you are considering this stock. ...read more

more
Index
TSX Composite
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
48 41 39 45
Growth
21 29 41 15
Safety
Safety
96 89 91 68
Sentiment
16 86 87 50
360° View
360° View
37 74 80 40
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
32 75 49 69
Opinions Change
50 50 50 50
Pro Holdings
n/a 55 73 16
Market Pulse
43 85 93 64
Sentiment
16 86 87 50
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
48 41 39 45
Growth
21 29 41 15
Safety Safety
96 89 91 68
Combined
56 55 64 22
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
3 7 5 4
Price vs. Earnings (P/E)
74 59 60 64
Price vs. Book (P/B)
89 80 79 85
Dividend Yield
1 1 1 1
Value
48 41 39 45
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
58 15 18 45
Profit Growth
4 80 93 25
Capital Growth
31 24 29 1
Stock Returns
47 51 57 71
Growth
21 29 41 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
77 75 78 79
Refinancing
83 82 77 55
Liquidity
48 41 43 25
Safety Safety
96 89 91 68

Similar Stocks

Discover high‑ranked alternatives to Knight Therapeutics and broaden your portfolio horizons.

Russel Metals

TSX:RUS
Country: Canada
Industry: Trading & Distribution
Size: Medium
Full Stock Analysis

Canadian Utilities

TSX:CU
Country: Canada
Industry: Multi-Utilities
Size: Medium
Full Stock Analysis

The North West

TSX:NWC
Country: Canada
Industry: Food Retail
Size: Medium
Full Stock Analysis

Bio-Techne

NasdaqGS:TECH
Country: USA
Industry: Life Sciences Tools & Services
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.